Determinants of cognitive dysfunction in adults with sickle cell related stroke or suspected neurological morbidity.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
30 May 2024
Historique:
accepted: 25 05 2024
received: 08 06 2023
revised: 30 04 2024
medline: 30 5 2024
pubmed: 30 5 2024
entrez: 30 5 2024
Statut: aheadofprint

Résumé

The prognosis of sickle cell disease (SCD) in adults is determined primarily by damage to targeted organs such as the brain. Cognitive dysfunction in SCD is a common chronic neurological mani-festation but studies remain mostly descriptive in adults. The objective of this study was to better characterize the cognitive profile and the association between cognitive dysfunction and brain lesions. We included adult SCD patients referred for a neurological assessment. An adapted bat-tery of neuropsychological tests was used to assess cognitive deficits. Brain (white matter lesions or infarcts) or arterial (stenosis or occlusion) abnormalities were assessed using brain MRI/MRA and a cervical and transcranial Doppler ultrasound. The battery was completed in 96 patients. The cognitive profile was characterized by deficits in processing speed (58% (95% CI [48-68])), short-term memory (34% (95% CI [24-43])) and working memory (24% (95% CI [15-33])). Brain in-farcts were found in 56% of patients and intracranial vasculopathy in 49%. Twenty percent of pa-tients had no brain abnormalities. Processing speed dysfunction was associated with territorial in-farcts (OR 3.1, p=0.03) and education outside of France (OR 4.7, p=0.02). Short-term memory dysfunction was associated with territorial infarcts (OR 3.4, p=0.01) and a low educational level (OR 8.2, p=0.01). Working memory dysfunction was associated with a low educational level (OR 4.3, p=0.05) and vasculopathy (OR 3.7, p=0.03). Cognitive dysfunction appears to be a hallmark sign of SCD, particularly for adults with sickle cell related stroke or suspected neurological mor-bidity. Assessment of such dysfunction could be used in longitudinal follow up and clinical trials.

Identifiants

pubmed: 38815229
pii: 516310
doi: 10.1182/bloodadvances.2023010925
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Society of Hematology.

Auteurs

Despina Messimeris (D)

GHU-Paris Psychiatrie et Neurosciences, Hôpital Sainte Anne, F-75014 Paris, France, France.

Hugo Bismuth (H)

GHU-Paris Psychiatrie et Neurosciences, HÃ'pital Sainte Anne, F-75014 Paris, France, Paris, France.

Corentin Provost (C)

GHU-Paris Psychiatrie et Neurosciences, Hôpital Sainte Anne, F-75014 Paris, France, France.

Clémentine Emaer (C)

GHU-Paris Psychiatrie et Neurosciences, Hôpital Sainte Anne, F-75014 Paris, France, Paris, France.

Nicolas Mélé (N)

GHU-Paris Psychiatrie et Neurosciences, Hôpital Sainte Anne, F-75014 Paris, France, France.

Robert M Kitenge (RM)

Centre hospitalier Monkole, Kinshasa, Congo-Democratic Republic.

Jean Benoit Arlet (JB)

Internal medicine department, French National Sickle Cell Referral Center, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, 75015 Paris, Université Paris Cité, France.

Laure Joseph (L)

Internal medicine department, French National Sickle Cell Referral Center, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, 75015 Paris, Université Paris Cité, France, France.

Brigitte Ranque (B)

Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, France.

Pablo Bartolucci (P)

Paris Est Créteil University, UMGGR, France.

Pauline Narme (P)

Université Paris Cité, Laboratoire Mémoire Cerveau et Cognition, UR 7536, Institut de Psychologie, France, Boulogne-Billancourt, France.

David Calvet (D)

GHU-Paris Psychiatrie et Neurosciences, Hôpital Sainte Anne, F-75014 Paris, France, France.

Classifications MeSH